Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19186434 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | April 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18978008 | USE OF OLEANOLIC ACID-28-O-BETA-D-GLUCOPYRANOSIDE IN PREPARATION OF ANTI-COLITIS DRUG | December 2024 | September 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18960884 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | November 2024 | October 2025 | Allow | 11 | 3 | 0 | Yes | No |
| 18792077 | COLON-TARGETED ACTIVE AGENT DELIVERY CARRIER AND USES THEREOF | August 2024 | June 2025 | Allow | 10 | 3 | 0 | Yes | No |
| 18765449 | PREBIOTIC COMPOSITIONS AND METHODS OF PRODUCTION THEREOF | July 2024 | August 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18680557 | AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSES | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18654457 | USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAIN | May 2024 | August 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18641536 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | April 2024 | September 2025 | Allow | 17 | 2 | 0 | Yes | No |
| 18609604 | TREATMENT OF HEARING LOSS | March 2024 | October 2024 | Allow | 7 | 0 | 0 | No | No |
| 18687295 | PHARMACEUTICAL COMPOSITION | February 2024 | March 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18584219 | OPHTHALMIC SOLUTIONS | February 2024 | October 2025 | Abandon | 20 | 3 | 0 | No | No |
| 18430551 | FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE | February 2024 | December 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18424626 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | January 2024 | March 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18420540 | METHODS OF SELECTIVELY MODULATING GASTROINTESTINAL MICROBIAL GROWTH | January 2024 | April 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18417312 | LIQUID COMPOSITION COMPRISING GLUCOSE | January 2024 | August 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18397012 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | December 2023 | January 2025 | Abandon | 13 | 1 | 0 | Yes | No |
| 18528550 | Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With Radiation | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18527321 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | December 2023 | January 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18522850 | BODY MILK | November 2023 | September 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18521467 | PROCESS FOR EFFICIENT CROSS-LINKING OF HYALURONIC ACID | November 2023 | June 2025 | Allow | 19 | 2 | 0 | No | No |
| 18504043 | NUTRITIONAL COMPOSITIONS WITH MFGM AND CERTAIN HUMAN MILK OLIGOSACCHARIDES AND USES THEREOF | November 2023 | February 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18555982 | USE OF CHONDROITIN SULFATE FOR RELIEVING OCULAR PAIN | October 2023 | March 2025 | Allow | 17 | 2 | 0 | Yes | No |
| 18378985 | PERITONEAL DIALYSIS SOLUTION | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18476119 | METHODS AND COMPOSITIONS FOR EXTENDING LIFESPAN | September 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18237659 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | August 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18277642 | MODIFIED GUANINES | August 2023 | March 2026 | Allow | 31 | 0 | 0 | Yes | No |
| 18362656 | COMPOSITE VITAMIN COMPOSITION PROMOTING GASTROINTESTINAL SYSTEM MOTILITY | July 2023 | April 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18274166 | CONJUGATES WITH INHIBITORY RECEPTOR LIGANDS TO INDUCE ANERGY IN INSULIN-BINDING B CELLS | July 2023 | July 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18336419 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18329047 | NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND NUCLEOTIDES AND USES THEREOF FOR TREATING AND/OR PREVENTING ENTERIC VIRAL INFECTION | June 2023 | December 2025 | Allow | 30 | 2 | 0 | Yes | No |
| 18033866 | INJECTABLE COMPOSITION AND USE OF SAID COMPOSITION | April 2023 | March 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18301874 | Senolytic Compositions and Uses Thereof | April 2023 | January 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18031420 | CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME | April 2023 | January 2026 | Allow | 34 | 0 | 0 | Yes | No |
| 18132332 | ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD | April 2023 | February 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18131161 | TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE | April 2023 | October 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18130475 | TREATMENT OF ALPHAVIRUS-INDUCED INFLAMMATION | April 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18027732 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE | March 2023 | December 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 18245658 | TOPICAL ANTIVIRAL COMPOSITIONS COMPRISING HYALURONIC ACID AND CARRAGEENAN | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18181653 | NUTRITIONAL COMPOSITION FOR IMPROVING CELL MEMBRANES | March 2023 | June 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18044384 | New fluorinated hexoses | March 2023 | December 2025 | Allow | 33 | 1 | 0 | Yes | No |
| 18176631 | GLYCOCONJUGATION PROCESS | March 2023 | October 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18017013 | UTILIZATION OF VITAMIN B12 IN INHIBITING RENAL DISORDER | January 2023 | January 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18016245 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE | January 2023 | November 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17983992 | COMPOSITIONS COMPRISING AT LEAST ONE N-ACETYLATED AND AT LEAST ONE FUCOSYLATED OLIGOSACCHARIDE FOR USE IN THE PROMOTION OF DIGESTIVE CAPACITY IN INFANTS AND YOUNG CHILDREN | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17978214 | SENSITIVE OLIGONUCLEOTIDE SYNTHESIS USING SULFUR-BASED FUNCTIONS AS PROTECTING GROUPS AND LINKERS | November 2022 | December 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17977034 | METHOD AND COMPOSITION FOR IMPROVED HYDRATION IN ANIMALS | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17920720 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING VIRAL INFECTIONS | October 2022 | February 2026 | Allow | 40 | 1 | 0 | Yes | No |
| 17913545 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING FIBROSIS RESULTING FROM A CORONAVIRUS INFECTION | September 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17941487 | PHARMACEUTICAL COMPOSITION FOR INHIBITING POSTOPERATIVE ADHESIONS | September 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17802806 | Use of Albiflorin in Treatment of Coronavirus Pneumonia | August 2022 | October 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17802716 | METHODS OF IMPROVING BONE HEALTH | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17801337 | IMMUNOMODULATING IMINE-OXAZOLINE AZALIDES | August 2022 | January 2026 | Abandon | 41 | 2 | 0 | No | No |
| 17800584 | ANTI-OBESITY COMPOSITION AND COMPOSITION FOR ORAL ADMINISTRATION | August 2022 | October 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17798270 | COMPOSITION COMPRISING 2'-FL AND DFL FOR USE IN A METHOD FOR REDUCING PAIN | August 2022 | September 2025 | Allow | 38 | 0 | 0 | No | No |
| 17882412 | PHARMACEUTICAL COMBINATION HAVING POTENT ANTIVIRAL ACTIVITY AGAINST SINGLE-STRANDED RNA VIRUSES INCLUDING CORONAVIRUSES AND MONKEYPOX | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17760102 | GLUCOSE IN SOLID FORM AND PROCESS FOR MANUFACTURING GLUCOSE IN SOLID FORM | August 2022 | November 2025 | Allow | 40 | 1 | 0 | No | No |
| 17859071 | PHOTOISOMERIZED COMPOSITIONS OF ANTHOCYANINS AND METHODS OF MAKING AND USE THEREOF | July 2022 | March 2026 | Allow | 44 | 2 | 0 | Yes | No |
| 17756832 | COMPOSITIONS FOR USE IN THE REDUCTION OF PAIN AND/OR PERCEPTION OF PAIN IN INFANTS AND YOUNG CHILDREN | June 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17831535 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | June 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17804679 | IMMUNOGENIC COMPOSITION | May 2022 | June 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17780869 | MIXTURE OF HMOs | May 2022 | November 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17749876 | COMPOSITIONS AND METHODS FOR TREATING FACIAL VOLUME DEFECTS | May 2022 | February 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17772994 | IIMPROVED APPROACH TO REPAIR TISSUE DEFECTS BY BONDING INJECTABLE GELS TO NATIVE SOFT TISSUES | April 2022 | October 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17772291 | ANTI-C5 AGENT FOR TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) OR GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD | April 2022 | January 2025 | Allow | 33 | 2 | 0 | No | No |
| 17729711 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS | April 2022 | November 2025 | Allow | 43 | 1 | 0 | No | No |
| 17765784 | MEDIUM ADDITIVE FOR SUSPENSION CULTURE, MEDIUM COMPOSITION AND CULTURE METHOD | March 2022 | August 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17765059 | TREHALOSE FORMULATIONS AND USES THEREOF | March 2022 | March 2025 | Allow | 36 | 0 | 0 | No | No |
| 17763136 | Hydrogel Composition For Tissue Regeneration, And Support Prepared Using Same | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17676675 | METHOD FOR DEACETYLATION OF BIOPOLYMERS | February 2022 | March 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17633869 | a-GLUCOSIDASE INHIBITOR, INVERTASE INHIBITOR, AND SUGAR ABSORPTION INHIBITOR | February 2022 | June 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17592691 | INHALED IVERMECTIN | February 2022 | September 2025 | Allow | 44 | 4 | 0 | Yes | No |
| 17586381 | XYLOOLIGOSACCHARIDE AS A MULTIFUNCTIONAL PREBIOTIC | January 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17630313 | Antifungal composition comprising natamycin and at least one insecticide | January 2022 | August 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17628857 | TREATMENT COMPRISING SGLT INHIBITORS | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17625394 | FOOD COMPOSITION | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17567945 | Application of Sulfated Polysaccharides in Resisting novel Coronavirus | January 2022 | August 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17565201 | HYDROGELS HAVING TUNABLE CROSS-LINKING DENSITIES AND REVERSIBLE PHASE TRANSITIONS AND METHODS FOR THEIR USE | December 2021 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17623716 | HYDROGEL COMPOSITIONS AND USES THEREOF | December 2021 | August 2025 | Allow | 44 | 0 | 1 | No | No |
| 17621938 | COMPOSITIONS AND METHODS FOR MODULATING MICROBIOMES | December 2021 | December 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17621248 | FUNCTIONAL FOOD | December 2021 | July 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17615479 | HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-COELIAC WHEAT AND / OR GLUTEN SENSITIVITY | November 2021 | January 2025 | Abandon | 38 | 0 | 0 | No | No |
| 17611847 | MEDICAMENT AND COMBINATION PRODUCT USED FOR PREVENTING, ALLEVIATING AND/OR TREATING FIBROSIS, AND USE THEREOF | November 2021 | October 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17610951 | USE OF GINSENOSIDE M1 FOR TREATING CANCER | November 2021 | February 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17608837 | CHLORIDE INTRACELLULAR CHANNEL 1 FOR REGULATION OF FOOD INTAKE | November 2021 | March 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17608203 | COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOF | November 2021 | January 2025 | Allow | 39 | 1 | 0 | No | No |
| 17606313 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASES | October 2021 | January 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17605900 | CELLULOSE NANOCRYSTAL COMPOSITE AND METHOD FOR PRODUCING THE SAME | October 2021 | December 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17506227 | GLUCOSE INFUSION SOLUTION COMPOSITION | October 2021 | June 2025 | Allow | 43 | 4 | 0 | No | No |
| 17498200 | Edible Energy Composition | October 2021 | February 2026 | Allow | 52 | 2 | 0 | No | No |
| 17438712 | METHODS OF TREATING ACUTE CORONARY SYNDROMES | September 2021 | November 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17472604 | AEROSOL AND TOPICAL ADMINISTRATION OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, IN COMBINATION OR SEPARATELY, TO MITIGATE INFECTION BY ENVELOPED VIRUSES | September 2021 | April 2024 | Allow | 31 | 4 | 0 | Yes | No |
| 17435629 | METHOD AND KIT FOR DETECTING INFLUENZA VIRUS, AND METHOD FOR DIAGNOSING INFLUENZA VIRUS INFECTION | September 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17369791 | CYCLODEXTRIN DIMERS AND USES THEREOF | July 2021 | February 2026 | Allow | 56 | 4 | 1 | Yes | No |
| 17419068 | BRAIN-PENETRATING LIGAND AND DRUG CARRIER | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17418570 | HEAT STRESS RELIEVING AGENT | June 2021 | April 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17417049 | COMPOSITION AND METHOD FOR PROMOTING INTESTINAL BARRIER HEALING | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17416573 | A NUTRITIONAL COMPOSITION COMPRISING A COMBINATION OF HUMAN MILK OLIGOSACCHARIDES TO IMPROVE THE GASTROINTESTINAL BARRIER | June 2021 | December 2025 | Allow | 54 | 5 | 0 | Yes | No |
| 17292963 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | May 2021 | February 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17291481 | METHODS OF SUPPORTING GASTROINTESTINAL HOMEOSTASIS | May 2021 | November 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17286803 | PHARMACEUTICAL USE OF ANEMOSIDE B4 AGAINST ACUTE GOUTY ARTHRITIS | April 2021 | January 2025 | Allow | 45 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MILLER, DALE R.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MILLER, DALE R works in Art Unit 1693 and has examined 52 patent applications in our dataset. With an allowance rate of 73.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.
Examiner MILLER, DALE R's allowance rate of 73.1% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MILLER, DALE R receive 2.15 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MILLER, DALE R is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.1% benefit to allowance rate for applications examined by MILLER, DALE R. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 34.4% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 34.8% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 88% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 142.9% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.